N4 Pharma PLC Result of AGM (7885C)
June 19 2019 - 6:51AM
UK Regulatory
TIDMN4P
RNS Number : 7885C
N4 Pharma PLC
19 June 2019
19 June 2019
N4 Pharma Plc
("N4 Pharma" or the "Company")
Result of AGM
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for vaccines and
cancer treatments, announces that at its annual general meeting
("AGM"), held earlier today, all resolutions were duly passed. All
resolutions were passed on a show of hands. The results of the
proxy voting for the AGM is set out below.
% % of
Total of issued
Total votes % of votes Votes votes Total Votes share Votes
Resolution For(1) cast(2) Against cast(2) Cast(3) capital Withheld(4)
To receive
the annual
report and
audited
accounts
for the
year ended
31 December
1 2018 16,362,457 99.99 1,134 0.01 16,363,591 16.13 0
-------------------- ------------ ----------- --------- --------- ------------ --------- -------------
To re-elect
Luke Cairns
as a director
2 of the Company 16,332,857 99.99 1,134 0.01 16,333,991 16.10 29,600
-------------------- ------------ ----------- --------- --------- ------------ --------- -------------
To elect
John Chiplin
as a Director
3 of the Company 16,332,857 99.99 1,134 0.01 16,333,991 16.10 29,600
-------------------- ------------ ----------- --------- --------- ------------ --------- -------------
To elect
Chris Britten
as a Director
4 of the Company 16,332,857 99.99 1,134 0.01 16,333,991 16.10 29,600
-------------------- ------------ ----------- --------- --------- ------------ --------- -------------
To re-appoint
Saffery
Champness
LLP as auditor
and authorise
directors
to determine
5 their remuneration 16,334,857 99.85 25,000 0.15 16,359,857 16.12 3,734
-------------------- ------------ ----------- --------- --------- ------------ --------- -------------
Authority
to allot
6 shares 16,331,657 99.82 30,200 0.18 16,361,857 16.12 1.734
-------------------- ------------ ----------- --------- --------- ------------ --------- -------------
Authority
to disapply
pre-emption
7 rights 16,330,457 99.97 5,334 0.03 16,335,791 16.10 27,800
-------------------- ------------ ----------- --------- --------- ------------ --------- -------------
Notes:
1. Any proxy votes that were at the discretion of the Chairman
are included in the "Total Votes For" each resolution
2. Percentage of votes cast excludes Votes Withheld
3. Total Votes Cast do not include withheld votes
4. Votes Withheld are not votes in law and do not count in the
number of votes counted for or against a resolution
Enquiries:
N4 Pharma Plc Via Scott PR
Nigel Theobald, CEO
Allenby Capital Limited Tel: +44(0)203 328 5656
James Reeve/Asha Chotai
Scott PR Tel: +44(0)1477 539 539
Georgia Smith
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for vaccines and cancer treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for vaccines and cancer treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGBBGDLGUBBGCC
(END) Dow Jones Newswires
June 19, 2019 07:51 ET (11:51 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Apr 2024 to May 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
From May 2023 to May 2024